Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AmpliMed Corporation was founded in 1989 with the support of the University of Arizona Technology Development Corporation and is focused on the clinical development of chemotherapeutic agents for cancer. AmpliMed’s strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of blood cell counts), multi-drug resistance (treatment-induced resistance to many cancer drugs) and cardiac toxicity, frequently associated with current cancer therapy. The company’s lead product, AmplimexonÔ (imexon inj.), is undergoing NDA-directed clinical ( www.amplimed.com )
AmpliMed Corporation
4380 North Campbell Avenue Suite 205
Tucson, Arizona 85718
USA
Tel: (520) 529-1000
Fax: (520) 529-3001